GSK PLC Sponsored ADR (NYSE:GSK) Receives $44.13 Consensus Target Price from Analysts

Shares of GSK PLC Sponsored ADR (NYSE:GSK) have earned a consensus recommendation of “Reduce” from the ten analysts that are covering the stock, MarketBeat reports. Four analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $44.1250.

Several brokerages recently issued reports on GSK. HSBC reiterated a “reduce” rating on shares of GSK in a research report on Wednesday, December 10th. Jefferies Financial Group reissued a “buy” rating on shares of GSK in a report on Monday, October 27th. Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a report on Wednesday, January 14th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a research note on Friday. Finally, Bank of America upgraded GSK from an “underperform” rating to a “neutral” rating in a research note on Tuesday, November 25th.

GSK Stock Performance

GSK opened at $48.26 on Friday. The stock has a market cap of $98.37 billion, a price-to-earnings ratio of 13.63, a PEG ratio of 1.21 and a beta of 0.45. The company has a quick ratio of 0.55, a current ratio of 0.84 and a debt-to-equity ratio of 0.95. GSK has a 12-month low of $32.38 and a 12-month high of $51.46. The business has a 50 day moving average of $48.60 and a 200-day moving average of $43.59.

GSK (NYSE:GSK) last posted its earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.26 by $0.22. GSK had a return on equity of 48.64% and a net margin of 17.16%.The firm had revenue of $11.35 billion during the quarter, compared to the consensus estimate of $8.21 billion. During the same period last year, the company earned $0.50 earnings per share. The business’s quarterly revenue was up 6.7% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. On average, equities research analysts expect that GSK will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, January 8th. Shareholders of record on Friday, November 14th were given a dividend of $0.4171 per share. This represents a $1.67 annualized dividend and a dividend yield of 3.5%. The ex-dividend date was Friday, November 14th. GSK’s payout ratio is 48.02%.

Insider Transactions at GSK

In other GSK news, major shareholder Plc Gsk purchased 1,470,000 shares of the stock in a transaction on Thursday, December 11th. The stock was acquired at an average price of $19.00 per share, with a total value of $27,930,000.00. Following the completion of the acquisition, the insider owned 18,245,691 shares in the company, valued at $346,668,129. The trade was a 8.76% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 10.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On GSK

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of GSK during the second quarter worth about $25,000. CNB Bank purchased a new position in shares of GSK during the third quarter worth approximately $31,000. SOA Wealth Advisors LLC. raised its holdings in shares of GSK by 252.1% in the second quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 605 shares during the last quarter. CoreFirst Bank & Trust purchased a new position in shares of GSK in the 2nd quarter valued at approximately $33,000. Finally, Triumph Capital Management acquired a new position in shares of GSK in the third quarter valued at approximately $40,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.